Cargando…

Chromatin and Epigenetic Dysregulation of Prostate Cancer Development, Progression, and Therapeutic Response

SIMPLE SUMMARY: Chromatin and epigenetic alterations in cancer are responsible for a wide range of transcriptional changes that link DNA mutations to tumor phenotype. In this review, we explore studies describing recurrent epigenetic alterations in prostate cancer and highlight changes that occur du...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kukkonen, Konsta, Taavitsainen, Sinja, Huhtala, Laura, Uusi-Makela, Joonas, Granberg, Kirsi J., Nykter, Matti, Urbanucci, Alfonso
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268970/ https://www.ncbi.nlm.nih.gov/pubmed/34283056 http://dx.doi.org/10.3390/cancers13133325

Ejemplares similares

Fanconi anemia pathway regulation by FANCI in prostate cancer
por: Kaljunen, Heidi, et al.
Publicado: (2023)

Frequent mutation of the FOXA1 untranslated region in prostate cancer
por: Annala, Matti, et al.
Publicado: (2018)

Interleukin 10 mutant zebrafish have an enhanced interferon gamma response and improved survival against a Mycobacterium marinum infection
por: Harjula, Sanna-Kaisa E., et al.
Publicado: (2018)

Chromatin accessibility is associated with CRISPR-Cas9 efficiency in the zebrafish (Danio rerio)
por: Uusi-Mäkelä, Meri I. E., et al.
Publicado: (2018)

Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen
por: Kukkonen, Konsta, et al.
Publicado: (2022)

Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer
por: Taavitsainen, Sinja, et al.
Publicado: (2019)

Modes of immunosuppression in glioblastoma microenvironment
por: Lehtipuro, Suvi, et al.
Publicado: (2019)

The expression of AURKA is androgen regulated in castration-resistant prostate cancer
por: Kivinummi, Kati, et al.
Publicado: (2017)

Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity
por: Ketola, Kirsi, et al.
Publicado: (2021)

Whole-exome sequencing identifies germline mutation in TP53 and ATRX in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma
por: Nordfors, Kristiina, et al.
Publicado: (2018)

Erratum: Whole-exome sequencing identifies germline mutation in TP53 and ATRX in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma
por: Nordfors, Kristiina, et al.
Publicado: (2018)

Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer
por: Annala, Matti, et al.
Publicado: (2015)

Epigenetically altered miR-193b targets cyclin D1 in prostate cancer
por: Kaukoniemi, Kirsi M, et al.
Publicado: (2015)

Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas
por: Granberg, Kirsi J, et al.
Publicado: (2017)

Gene Regulation Network Analysis on Human Prostate Orthografts Highlights a Potential Role for the JMJD6 Regulon in Clinical Prostate Cancer
por: Cangiano, Mario, et al.
Publicado: (2021)

DOT1L-HES6 fusion drives androgen independent growth in prostate cancer
por: Annala, Matti, et al.
Publicado: (2014)

Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas
por: Lehtinen, Birgitta, et al.
Publicado: (2017)

CD109-GP130 interaction drives glioblastoma stem cell plasticity and chemoresistance through STAT3 activity
por: Filppu, Pauliina, et al.
Publicado: (2021)

Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
por: Taavitsainen, S., et al.
Publicado: (2021)

Editorial: Epigenetic and Transcriptional Dysregulations in Cancer and Therapeutic Opportunities
por: Ansari, Rais A., et al.
Publicado: (2022)

Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals
por: Bosutti, Alessandra, et al.
Publicado: (2016)

Data-driven characterization of molecular phenotypes across heterogeneous sample collections
por: Mehtonen, Juha, et al.
Publicado: (2019)

Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine
por: Nurminen, Anssi, et al.
Publicado: (2023)

Proteomics of prostate cancer – revealing how cancer cells master their messy genomes
por: Latonen, Leena, et al.
Publicado: (2018)

Epigenetic dysregulation in glioma
por: Kondo, Yutaka, et al.
Publicado: (2014)

Epigenetic dysregulation in meningiomas
por: Wedemeyer, Michelle A, et al.
Publicado: (2022)

Chromatin dysregulation by mutant p53
por: Pfister, Neil T., et al.
Publicado: (2016)

Characterization of the innate immune response to Streptococcus pneumoniae infection in zebrafish
por: Saralahti, Anni K., et al.
Publicado: (2023)

Welcome to Epigenetics & Chromatin
por: Henikoff, Steven, et al.
Publicado: (2008)

Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer
por: Barfeld, Stefan J., et al.
Publicado: (2015)

Corrigendum to: Epigenetic dysregulation in meningiomas
Publicado: (2023)

Dysregulation of MITF Leads to Transformation in MC1R-Defective Melanocytes
por: Lavelle, Timothy J., et al.
Publicado: (2020)

Dysregulation of DNA Methylation and Epigenetic Clocks in Prostate Cancer among Puerto Rican Men
por: Berglund, Anders, et al.
Publicado: (2021)

Feature-based analysis of mouse prostatic intraepithelial neoplasia in histological tissue sections
por: Ruusuvuori, Pekka, et al.
Publicado: (2016)

Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer
por: Vandekerkhove, Gillian, et al.
Publicado: (2021)

Decoding the epigenetic effects of chromatin
por: Festenstein, Richard, et al.
Publicado: (2003)

Epigenetics & chromatin: interactions and processes
por: Henikoff, Steven, et al.
Publicado: (2013)

Chromatin, Epigenetics and Plant Physiology
por: Fojtová, Miloslava, et al.
Publicado: (2020)

IGFBP2 potentiates nuclear EGFR-STAT3 signaling
por: Chua, Corrine Yingxuan, et al.
Publicado: (2015)

Epigenetic modulators as therapeutic targets in prostate cancer
por: Graça, Inês, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_svdq2o2co8n52kupltja31k7jb